Clinical Trial Update: Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy [Phase 1]

View source ↗

Summary

Ongoing Phase 1 trial update for 225Ac-ABD147 to establish the optimal dose in patients with small-cell lung cancer and large cell neuroendocrine carcinoma of t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large Cell Neuroendocrine Carcinoma of the Lung
• Small Cell Lung Cancer

Drugs mentioned

• 225Ac-ABD147

Snippet

Sponsor: Abdera Therapeutics Inc. | Conditions: Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Status: ACTIVE_NOT_RECRUITING